FDA Issues Proposed Rule Amending Regulations Regarding Acceptance of Data from Clinical Studies for Medical Devices

more+
less-

On February 25, 2013, the U.S. Food and Drug Administration (FDA) released a proposed rule entitled Human Subject Protection: Acceptance of Data From Clinical Studies for Medical Devices. The proposed rule would require that clinical studies conducted outside the U.S. (“foreign clinical studies”) provided in investigational device exemption applications (IDE) or premarket submissions, including 510(k), Premarket Approvals (PMA), Humanitarian Device Exemptions (HDE), and Product Development Protocols (PDP) submissions, comply with Good Clinical Practices (GCP) or provide a justification for not complying with the GCP requirements. In addition, the proposed rule would require that clinical studies conducted inside the United States (“U.S. clinical studies”) and provided in IDEs and premarket notifications (510(k) submissions) comply with the applicable provisions of FDA’s existing regulations regarding the protection of human subjects, institutional review boards (IRBs), and IDE requirements as set forth in 21 C.F.R. Parts 50, 56, and 812, respectively. The proposed rule is intended to ensure the protection of human subjects and the integrity and quality of the data submitted. It is also intended to standardize the criteria for FDA’s acceptance of clinical data in support of IDE and premarket submissions. Comments on the proposed rule must be submitted by May 28, 2013.

I. Proposed Inclusion of Good Clinical Practice in the IDE Regulations -

The proposed rule would incorporate the GCP requirements for acceptance of foreign clinical studies in FDA’s investigational new drug application (IND) regulations into the IDE regulations by...

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

FDA

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×
Loading...
×
×